BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guh AY, Hatfield KM, Winston LG, Martin B, Johnston H, Brousseau G, Farley MM, Wilson L, Perlmutter R, Phipps EC, Dumyati GK, Nelson D, Hatwar T, Kainer MA, Paulick AL, Karlsson M, Gerding DN, McDonald LC. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates. Clin Infect Dis 2019;69:1667-74. [PMID: 30615074 DOI: 10.1093/cid/ciz009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Shah MD, Balada-Llasat JM, Coe K, Reed E, Sandlund J, Pancholi P. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results. J Clin Microbiol 2020;58:e01681-19. [PMID: 32051264 DOI: 10.1128/JCM.01681-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gerding DN. Incidence and Outcome of Clostridium difficile Infection-Beware of Strain Type and Diagnostic Tests. JAMA Netw Open 2020;3:e1918599. [PMID: 31913485 DOI: 10.1001/jamanetworkopen.2019.18599] [Reference Citation Analysis]
3 Johnson S. The Rise and Fall and Rise Again of Toxin Testing for the Diagnosis of Clostridioides difficile Infection. Clinical Infectious Diseases 2019;69:1675-7. [DOI: 10.1093/cid/ciz012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
4 Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med 2020;10:E2. [PMID: 33374989 DOI: 10.3390/jcm10010002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sullivan KV, Gallagher JC, Leekha S, Morgan DJ, Morita K, Rock C, Claeys KC. Use of diagnostic and antimicrobial stewardship practices to improve Clostridioides difficile testing among SHEA Research Network hospitals. Infect Control Hosp Epidemiol 2021;:1-5. [PMID: 34376271 DOI: 10.1017/ice.2021.133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Miller R, Morillas JA, Brizendine KD, Fraser TG. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients. J Clin Microbiol 2020;58:e01764-19. [PMID: 31896665 DOI: 10.1128/JCM.01764-19] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Nagayoshi Y, Yamamoto K, Sato S, Suyama N, Izumikawa T, Izumikawa K, Miyazaki T, Izumikawa K, Yanagihara K, Mukae H. Clinical significance of a positive Clostridioides difficile glutamate dehydrogenase test on the outcomes of hospitalized older patients. Geriatr Gerontol Int 2020;20:1138-44. [PMID: 33098238 DOI: 10.1111/ggi.14054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Skinner AM, Yu B, Cheknis A, Pacheco SM, Gerding DN, Johnson S. Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity. Infect Control Hosp Epidemiol 2020;41:1148-53. [PMID: 32576334 DOI: 10.1017/ice.2020.267] [Reference Citation Analysis]
9 Martins JP, Felgueiras M, Santos R. The reference method influence on the sensitivity of the Clostridium difficile enzyme immunoassays: A meta analysis. J Microbiol Methods 2020;173:105912. [PMID: 32278778 DOI: 10.1016/j.mimet.2020.105912] [Reference Citation Analysis]
10 Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211016248. [PMID: 34093740 DOI: 10.1177/17562848211016248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
12 Menon A, Perry DA, Motyka J, Weiner S, Standke A, Penkevich A, Keidan M, Young VB, Rao K. Changes in the Association between Diagnostic Testing Method, PCR Ribotype, and Clinical Outcomes from Clostridioides difficile Infection: One Institution's Experience. Clin Infect Dis 2020:ciaa1395. [PMID: 32930705 DOI: 10.1093/cid/ciaa1395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Boly FJ, Reske KA, Kwon JH. The Role of Diagnostic Stewardship in Clostridioides difficile Testing: Challenges and Opportunities. Curr Infect Dis Rep 2020;22:7. [PMID: 33762897 DOI: 10.1007/s11908-020-0715-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Sullivan KV. Diagnostic Stewardship in Clinical Microbiology, Essential Partner to Antimicrobial Stewardship. Clinical Chemistry 2022;68:75-82. [DOI: 10.1093/clinchem/hvab206] [Reference Citation Analysis]
15 Olmedo M, Alcalá L, Valerio M, Marín M, Onori R, Reigadas E, Muñoz P, Bouza E. Three different patterns of positive Clostridium difficile laboratory tests. A comparison of clinical behavior. Diagn Microbiol Infect Dis 2020;97:115050. [PMID: 32482380 DOI: 10.1016/j.diagmicrobio.2020.115050] [Reference Citation Analysis]
16 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Reference Citation Analysis]